Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia

Area of Science:

• Hematology
• Oncology
• Clinical Trials

Background:

• Interim analysis indicated ibrutinib-venetoclax superiority over FCR in CLL.
• Efficacy of ibrutinib-venetoclax versus ibrutinib monotherapy remained undetermined.

Purpose of the Study:

• To compare undetectable MRD rates between ibrutinib-venetoclax and ibrutinib alone.
• To evaluate progression-free survival for ibrutinib-venetoclax against both ibrutinib alone and FCR.

Main Methods:

• Phase 3, multicenter, open-label randomized trial.
• Patients with CLL assigned to ibrutinib-venetoclax, ibrutinib alone, or FCR.
• Primary endpoints: undetectable MRD and progression-free survival.

Main Results:

• 66.2% of ibrutinib-venetoclax patients achieved undetectable MRD vs. 0% for ibrutinib alone and 48.3% for FCR.
• 5-year progression-free survival: 93.9% (ibrutinib-venetoclax), 79.0% (ibrutinib alone), 58.1% (FCR).
• Ibrutinib-venetoclax showed significantly lower rates of progression, death, and improved overall survival.

Conclusions:

• Ibrutinib-venetoclax demonstrated superior undetectable MRD and extended progression-free survival versus ibrutinib alone and FCR.
• Overall survival data also supported a benefit for the ibrutinib-venetoclax combination therapy.